- Abigail Coursolle
- Alejandra Pavisich
- Alejandra Pavisich
- Alexis Robles-Fradet
- Alicia Emanuel
- Allyson Crays
- Amanda Avery
- Amani Echols
- Amy Chen
- Andy DiAntonio
- Arielle Linsey
- Ash Bliss
- Brian Brooks
- Brit Vanneman
- Brit Vanneman
- California Policy Team
- Candace Gibson
- Carly Myers
- Cassandra LaRose
- Cat Duffy
- Catherine McKee
- Cathren Cohen
- Charlie Blodnieks
- Charly Gilfoil
- Cheyenne Peters
- Christina Piecora
- Corey Davis
- Dania Douglas
- Daniel Young
- David Machledt
- Deanna Hartog
- Dylan de Kervor
- Elizabeth Edwards
- Elizabeth G. Taylor
- Elizabeth Zirker
- Emma Parker-Newton
- Eskedar Girmash
- Fabiola De Liban
- Fabiola De Liban
- Georgesula Ziama
- Geraldine Doetzer
- Geron Gadd
- Hannah Eichner
- Hayley Penan
- Héctor Hernández-Delgado
- Ian Anderson
- Ian McDonald
- Jane Perkins
- Jasmine Young
- Jennifer Cannistra
- Jennifer Lav
- Joe McLean
- Jules Lutaba
- Kally Xu
- Kasey Nichols
- Katy DeBriere
- Kavisha Prajapati
- Kimberly Lewis
- Leonardo Cuello
- Liz McCaman Taylor
- Madeline Morcelle
- Mara Youdelman
- Margaret Okakpu
- Maya Levin
- Michelle Lilienfeld
- Michelle Yiu
- Miriam Delaney Heard
- Mizue Suito
- Priscilla Huang
- Rachel Holtzman
- Rachel Utz
- Rolonda Donelson
- Sarah Grusin
- Sarah Somers
- Shandra Hartly
- Shandra Hartly
- Skyler Rosellini
- Steven Schmidt
- Susan Berke Fogel
- T. Nancy Lam
- Walter Hsiang, MD
- Wayne Turner
- Zamir M. Brown
- Show all
- Alabama
- Alaska
- All United States
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- National
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- Show all
- 1557
- 50th Anniversary
- Abortion
- Admin and Procedural Barriers
- ADS Evergreen
- Affordable Care Act
- Assisted Reproduction
- Automated Decision Making
- Behavioral Health
- Child and Adolescent Health
- CHIP
- Civil Procedure
- Civil Rights
- Coronavirus
- Cost-sharing
- Court Access
- COVID-19 Public Health Emergency
- Data Collection
- Defending Medicaid
- Delivery System Featured
- Delivery System Reform
- Demonstrations
- Disability
- Disability Rights
- Doula Care
- Dual Eligible Beneficiaries
- Eligibility and Enrollment
- EPSDT
- Exchanges/Marketplaces
- Family Planning
- Federal and State Court Cases
- Foster youth
- HCBS/LTSS
- Health Care Reform
- Health Care Refusals
- Health Disparities
- Health Reform
- HIV/AIDS and Sexual Health
- Home and Community Based Services
- Immigrant Health
- Language Access
- LGBTQ Health
- Litigation
- Managed Care
- Medi-Cal
- Medicaid
- Medicaid Awareness Month
- Medicaid Awareness Month 2024
- Medicaid Defense 2025
- Mental Health
- Nondiscrimination
- Opioid Use Disorder
- Oral Health
- Post-OBBBA Medi-Cal Defense (California)
- Post-OBBBA Medicaid & ACA Defense
- Pregnancy
- Prescription Drugs Marketplace
- Prescription Drugs Medicaid
- Privacy and Confidentiality
- Protect Medicaid 2023
- Public Charge
- Public Health
- Refusals of SRH Care
- Reproductive Health
- Services
- Sexual and Reproductive Health (SRH)
- Sexual Health
- SRH Equity
- SRH Equity for Immigrants
- SRH Equity for LGBTQI+ People
- SRH Equity for People of Color
- SRH Equity for People with Disabilities
- SRH Equity for Young People
- SRH Nondiscrimination
- SRH Post-OBBBA
- Supreme Court
- Telehealth
- Telehealth Abortion Coverage
- Waivers and Demonstrations
- Women's Health
- Work Requirements
- December 14, 2018
Comments to the FDA Urging Approval of Over the Counter Naloxone
Read moreThe National Health Law Program strongly urges the Food and Drug Administration (FDA) to initiate the process of moving at least one naloxone product from prescription to over the counter (OTC) status. Naloxone, a safe and effective medication, reverses opioid overdose if given in time, but is often not…
- July 16, 2018
National Health Law Program Comments on HHS Plan to Lower Drug Prices
Read moreThe Department of Health and Human Services (HHS) published a Request for Information seeking comments on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. National Health Law Program's response, filed July 16 focuses on three key areas that the HHS Blueprint addresses only in part, or overlooks completely:…
- December 1, 2016
Fact Sheet: Utilization Controls for Medicaid Prescription Drugs
Abbi Coursolle and Andy DiAntonio Manual/ReportRead moreState Medicaid programs that elect to provide outpatient prescription drug coverage must cover all FDA-approved drugs that are offered by a manufacturer that agrees to provide rebates. Nevertheless, states have substantial discretion to use utilization control techniques to steer Medicaid beneficiaries toward or away from certain drugs, within limits.…
- November 30, 2016
Fact Sheet: Medicaid Outpatient Prescription Drugs
Read morePrescription drug coverage is an important facet of the Medicaid program. Although an optional benefit, all states cover outpatient prescription drugs in their Medicaid programs.This fact sheet provides an overview of Medicaid outpatient prescription drug coverage, including: federal minimum requirements, state restrictions on prescription drug access, and special rules…
April 26, 2016Covered California: 2016 Benefit Designs: Cost Sharing for Prescription Drugs & Tiered Network Designs
Abbi Coursolle, Kim Lewis, and Andy DiAntonio LetterRead more- March 7, 2016
NHeLP Comments to the Senate Finance Committee on the High Price of Prescription
Read moreNHeLP letter to the Senate Finance Committee in response to the request for public comment on policy issues including the financial impact of high prices of breakthrough drugs, data on prescription drug costs, and ensuring patient access, particularly for low income and vulnerable populations. Commments follow after an 18 month investigation…